Market Research Reports

Molecular Diagnostics Market (PCR, Next Generation Sequencing, Microarray, Infectious diseases, Genetic disease, Oncology testing, Blood donor screening) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

122pages
Published Date: 2014-02-06
 

Description


Molecular diagnostics is defined as a class of diagnostic tests which identifies genetic and molecular biomarkers of an individual patient. It is essentially an analysis of RNA and DNA at the molecular level. This class of diagnostics tests is considered as the most well established and lucrative market in the clinical applications segment. Traditionally, usage of molecular diagnostics was limited due to requirement of highly skilled professionals and high cost of tests. However, recent reduction in cost per sample analysis, labor costs, improvements in automation and introduction of advanced technologies have expanded the usage of molecular diagnostics tests. The growth of this market is expected to surge due to various factors such as rise in incidence of hospital acquired infections, increase in patient awareness along with growing elderly population. Additionally, outbreak of diseases such as H1N1, growing incidence of diseases such as HIV and hepatitis have augmented the growth of this market.

The research report on molecular diagnostics provides detailed analysis of the global market and helps in understanding the driving forces responsible for its growth. The report discusses the molecular diagnostics market on the basis of different technologies and applications. The technology segment comprises polymerase chain reaction (PCR), transcription mediated amplification (TMA), hybridization technique, microarray, next generation sequencing and others. The application segment is classified into infectious diseases, blood donor screening and genomics. The genomics segmented is further classified into genetic disorders testing, oncology testing, HLA testing and pharmacogenetic testing. The infectious diseases segment is subsegmented into virology and bacteriology. The virology section of the report deals with testing of following infections namely, HIV (Human immunodeficiency virus), HPV (Human papillomavirus), HCV (Hepatitis C virus) and others. The bacteriology segment of the report is further categorized into hospital acquired infections (HAI), CT/NG (Chlamydia trachomatis and Neisseria gonorrhoeae) and others. Market size estimates and forecasts for the period 2011 to 2019 have been provided for each of the segments in terms of USD million using 2012 as the base year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has been provided along with market size estimations.

The molecular diagnostics market has also been segmented geographically into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW), and respective market sizes and forecasts have been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global molecular diagnostics market, and future opportunities has been provided in the market overview section. This section also features a detailed market attractiveness analysis and Porter’s five forces analysis for the molecular diagnostics market that would help in determining the degree of competition in the market. The entire section of market overview plays an important role in understanding the market on a global level. Further, the report on molecular diagnostics also provides executive summary that that will help you understand the overall market size, growth rate of various segments, geographies and competitors present in the market in a very precise manner.

The molecular diagnostics market report also provides a highlight of the competitive landscape of the market wherein the market share analysis of the leading players in the market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the molecular diagnostics market such as Abbott Laboratories, Becton Dickinson & Company, Cepheid, Roche Diagnostics and others. Profiles of these players have been extensively analyzed on the basis of company overview, financial overview, business strategies, product portfolio and recent developments.
The global molecular diagnostics market is segmented into the following categories:
  • Molecular Diagnostics Market, by Technology
    • PCR
    • Transcription mediated amplification (TMA)
    • Next generation sequencing
    • Microarray
    • Hybridization techniques
    • Others
  • Molecular Diagnostics Market, by Application
    • Infectious diseases
      • Virology
        • HIV testing
        • HPV testing
        • HCV testing
        • Others
      • Bacteriology
        • HAI testing
        • CT/NG testing
        • Others
    • Genomics
      • Genetic testing for inherited disorders
      • Human Leukocyte Antigen (HLA) testing
      • Pharmacogenetics testing
      • Oncology Testing
    • Blood Donor Screening
    • Others
  • Molecular Diagnostics Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • RoW

Table of Contents


Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Molecular Diagnostics Market (2012 & 2019)
2.2 Global Molecular Diagnostics Market, by Technology, 2012 (USD Million)

Chapter 3 Market Overview
3.1 Overview
3.2 Market Drivers
      3.2.1 Rising incidence of cancer cases
      3.2.2 Aging population
      3.2.3 Increase in incidence of chronic diseases
      3.2.4 Increasing awareness and acceptance of companion diagnostics and personalized medicines
3.3 Market Restraints
      3.3.1 Issues with reimbursement policies
3.4 Market Opportunities
      3.4.1 Technological advancements
      3.4.2 Tapping the emerging economies
3.5 Porter’s Five Force Analysis: Global Molecular Diagnostics Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of New Entrants
      3.5.4 Threat of Substitutes
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis of the Global Molecular Diagnostics Market, by Geography

Chapter 4 Molecular Diagnostics Market, by Technology
4.1 Overview
      4.1.1 Global Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
4.2 Polymerase Chain Reaction (PCR)
      4.2.1 Global PCR Market, 2011 – 2019 (USD Million)
4.3 Transcription Mediated Amplification (TMA)
      4.3.1 Global TMA Market, 2011 – 2019 (USD Million)
4.4 Microarray
      4.4.1 Global Microarray Market, 2011 – 2019 (USD Million)
4.5 Hybridization (ISH and FISH)
      4.5.1 Global Hybridization Market, 2011 – 2019 (USD Million)
4.6 Next-generation sequencing
      4.6.1 Global Next generation sequencing Market, 2011 – 2019 (USD Million)
4.7 Others
      4.7.1 Global Others Market, 2011 – 2019 (USD Million)

Chapter 5 Global Molecular Diagnostics Market, by  Applications
5.1 Overview
      5.1.1 Global Molecular Diagnostics Market, by Applications, 2011 – 2019 (USD Million)
5.2 Infectious Diseases
      5.2.1 Global Infectious Diseases Market, by Segments, 2011 – 2019 (USD Million)
      5.2.2 Virology
               5.2.2.1 Global Virology Market, by Segments, 2011 – 2019 (USD Million)
               5.2.2.2 Human immunodeficiency virus (HIV) testing
                          5.2.2.2.1 Global HIV testing Market, 2011 – 2019 (USD Million)
               5.2.2.3 Human papillomavirus (HPV) testing
                          5.2.2.3.1 Global HPV testing Market, 2011 – 2019 (USD Million)
               5.2.2.4 Hepatitis C virus (HCV) testing
                          5.2.2.4.1 Global HCV testing Market, 2011 – 2019 (USD Million)
               5.2.2.5 Others
                           5.2.2.5.1 Global Others testing Market, 2011 – 2019 (USD Million)
      5.2.3 Bacteriology
               5.2.3.1 Global Bacteriology Market, by Segments, 2011 – 2019 (USD Million)
               5.2.3.2 Hospital Acquired Infection (HAI) testing
                          5.2.3.2.1 Global HAI testing Market, 2011 – 2019 (USD Million)
               5.2.3.3 Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) testing
                          5.2.3.3.1 Global CT/NG testing Market, 2011 – 2019 (USD Million)
              5.2.3.4 Others
                         5.2.3.4.1 Global Others testing Market, 2011 – 2019 (USD Million)
5.3 Genomics
      5.3.1 Global Genomics Market, by Segments, 2011 – 2019 (USD Million)
      5.3.2 Genetic testing for inherited disorders
               5.3.2.1 Global Genetic testing for inherited disorders Market, 2011 – 2019 (USD Million)
      5.3.3 Human Leukocyte Antigen (HLA)testing
              5.3.3.1 Global HLA testing Market, 2011 – 2019 (USD Million)
      5.3.4 Pharmacogenetics testing
               5.3.4.1 Global Pharmacogenetics testing Market, 2011 – 2019 (USD Million)
      5.3.5 Oncology testing
              5.3.5.1 Global Oncology testing Market, 2011 – 2019 (USD Million)
5.4 Blood Donor Screening
      5.4.1 Global Blood donor screening testing Market, 2011 – 2019 (USD Million)
5.5 Others
      5.5.1 Global Others testing Market, 2011 – 2019 (USD Million)

Chapter 6 Global Molecular Diagnostics Market, by Geography
6.1 Overview
      6.1.1 Global Molecular Diagnostics Market, by Geography, 2011 – 2019 (USD Million)
6.2 Comparative Analysis: Molecular Diagnostics Market, by Geography, 2012 & 2019 (Value %)
6.3 North America
      6.3.1 North America Molecular Diagnostics Market, by Application, 2011 – 2019 (USD Million)
      6.3.2 North America Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
6.4 Europe
      6.4.1 Europe Molecular Diagnostics Market, by Application, 2011 – 2019 (USD Million)
      6.4.2 Europe Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
6.5 Asia-Pacific
      6.5.1 Asia Pacific Molecular Diagnostics Market, by Application, 2011 – 2019 (USD Million)
      6.5.2 Asia-Pacific Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
6.6 RoW
      6.6.1 RoW Molecular Diagnostics Market, by Application, 2011 – 2019 (USD Million)
      6.6.2 RoW Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)

Chapter 7 Global Molecular Diagnostics Market Share Analysis
7.1 Market Share Analysis by Key Players of Global Molecular Diagnostics Market
      7.1.1 Global Molecular Diagnostics Market Share Analysis, by Key Players, 2012 (%)
      7.1.2 Competitive Position of Key Players by Segment : Global Molecular Diagnostics Market

Chapter 8 Recommendations
8.1 Market Strategies for Success
      8.1.1 Long term contracts with healthcare service providers
      8.1.2 Investing in emerging economies such as China, India and Russia
      8.1.3 Broadening of distribution network

Chapter 9 Company Profiles
9.1 Abbott Laboratories
      9.1.1 Company Overview
      9.1.2 Financial Overview
      9.1.3 Product Portfolio
      9.1.4 Business Strategies
      9.1.5 Recent Developments
9.2 Becton Dickinson & Company
      9.2.1 Company Overview
      9.2.2 Financial Overview
      9.2.3 Product Portfolio
      9.2.4 Business Strategies
      9.2.5 Recent Developments
9.3 bioMerieux
      9.3.1 Company Overview
      9.3.2 Financial Overview
      9.3.3 Product Portfolio
      9.3.4 Business Strategies
      9.3.5 Recent Developments
9.4 Bio-Rad
      9.4.1 Company Overview
      9.4.2 Financial Overview
      9.4.3 Product Portfolio
      9.4.4 Business Strategies
      9.4.5 Recent Developments
9.5 Cepheid
      9.5.1 Company Overview
      9.5.2 Financial Overview
      9.5.3 Product Portfolio
      9.5.4 Business Strategies
      9.5.5 Recent Developments
9.6 Danaher Corporation (Beckman Coulter)
      9.6.1 Company Overview
      9.6.2 Financial Overview
      9.6.3 Product Portfolio
      9.6.4 Business Strategies
      9.6.5 Recent Developments
9.7 F. Hoffmann-La Roche Ltd.
      9.7.1 Company Overview
      9.7.2 Financial Overview
      9.7.3 Product Portfolio
      9.7.4 Business Strategies
      9.7.5 Recent Developments
9.8 Hologic, Inc. (Gen-Probe)
      9.8.1 Company Overview
      9.8.2 Financial Overview
      9.8.3 Product Portfolio
      9.8.4 Business Strategies
      9.8.5 Recent Developments
9.9 Myriad Genetics, Inc.
      9.9.1 Company Overview
      9.9.2 Financial Performance
      9.9.3 Product Portfolio
      9.9.4 Business Strategies
      9.9.5 Recent Developments
9.10 Novartis International AG
      9.10.1 Company Overview
      9.10.2 Financial Overview
      9.10.3 Product Portfolio
      9.10.4 Business Strategies
9.11 Qiagen
      9.11.1 Company Overview
      9.11.2 Financial Overview
      9.11.3 Product Portfolio
      9.11.4 Business Strategies
      9.11.5 Recent Developments
9.12 Quest Diagnostics, Inc.
      9.12.1 Company Overview
      9.12.2 Financial Overview
      9.12.3 Product Portfolio
      9.12.4 Business Strategies
      9.12.5 Recent Developments
9.13 Siemens AG
      9.13.1 Company Overview
      9.13.2 Financial Overview
      9.13.3 Product Portfolio
      9.13.4 Business Strategies
      9.13.5 Recent Developments
9.14 Thermo Fisher Scientific
      9.14.1 Company Overview
      9.14.2 Financial Overview
      9.14.3 Product Portfolio
      9.14.4 Business Strategies
      9.14.5 Recent Developments

List of Figures

FIG. 1 Molecular Diagnostics: Market Segmentation
FIG. 2 Global Molecular Diagnostics Market, by Technology, 2012 (USD Million)
FIG. 1 Porter’s Five Force Analysis: Global Molecular Diagnostics Market
FIG. 2 Market Attractiveness Analysis : Global Molecular Diagnostics Market, by Geography
FIG. 3 Global PCR Market, 2011 – 2019 (USD Million)
FIG. 4 Global TMA Market, 2011 – 2019 (USD Million)
FIG. 5 Global Microarray Market, 2011 – 2019 (USD Million)
FIG. 6 Global Hybridization Market, 2011 – 2019 (USD Million)
FIG. 7 Global Next generation sequencing Market, 2011 – 2019 (USD Million)
FIG. 8 Global Others Market, 2011 – 2019 (USD Million)
FIG. 9 Global HIV testing Market, 2011 – 2019 (USD Million)
FIG. 10 Global HPV testing Market, 2011 – 2019 (USD Million)
FIG. 11 Global HCV testing Market, 2011 – 2019 (USD Million)
FIG. 12 Global Others testing Market, 2011 – 2019 (USD Million)
FIG. 13 Global HAI testing Market, 2011 – 2019 (USD Million)
FIG. 14 Global CT/NG testing Market, 2011 – 2019 (USD Million)
FIG. 15 Global Others testing Market, 2011 – 2019 (USD Million)
FIG. 16 Global Genetic testing for inherited disorders Market, 2011 – 2019 (USD Million)
FIG. 17 Global HLA testing Market, 2011 – 2019 (USD Million)
FIG. 18 Global Pharmacogenetics testing Market, 2011 – 2019 (USD Million)
FIG. 19 Global Oncology testing Market, 2011 – 2019 (USD Million)
FIG. 20 Global Blood donor screening testing Market, 2011 – 2019 (USD Million)
FIG. 21 Global Others testing Market, 2011 – 2019 (USD Million)
FIG. 22 Comparative Analysis: Molecular Diagnostics Market, by Geography, 2012 & 2019 (Value %)
FIG. 23 Global Molecular Diagnostics: Market Share, by Key Players, 2012 (%)
FIG. 24 Abbott Laboratories, Inc., Annual Revenue, 2010 – 2012 (USD Million)
FIG. 25 Becton Dickinson: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 26 bioMerieux: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 27 Bio-Rad: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 28 Cepheid: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 29 Danaher Corporation: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 30 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 31 Hologic, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 32 Myriad Genetics, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 33 Novartis International AG.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 34 Qiagen N.V.,: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 35 Quest Diagnostics: Annual Revenue,2010 – 2012 (USD Million)
FIG. 36 Siemens AG : Annual Revenue, 2010 – 2012 (USD Million)
FIG. 37 Thermo Fisher Scientific: Annual Revenue,2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Molecular Diagnostics Market (2012 & 2019)
TABLE 2 Global Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
TABLE 3 Global Molecular Diagnostics Market, by Applications, 2011 – 2019 (USD Million)
TABLE 4 Global Infectious Diseases Market, by Segments, 2011 – 2019 (USD Million)
TABLE 5 Global Virology Market, by Segments, 2011 – 2019 (USD Million)
TABLE 6 Global Bacteriology Market, by Segments, 2011 – 2019 (USD Million)
TABLE 7 Global Genomics Market, by Segments, 2011 – 2019 (USD Million)
TABLE 8 Global Molecular Diagnostics Market, by Geography, 2011 – 2019 (USD Million)
TABLE 9 North America Molecular Diagnostics Market, by Application, 2011 – 2019 (USD Million)
TABLE 10 North America Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
TABLE 11 Europe Molecular Diagnostics Market, by Application, 2011 – 2019 (USD Million)
TABLE 12 Europe Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
TABLE 13 Asia Pacific Molecular Diagnostics Market, by Application, 2011 – 2019 (USD Million)
TABLE 14 Asia-Pacific Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
TABLE 15 RoW Molecular Diagnostics Market, by Application, 2011 – 2019 (USD Million)
TABLE 16 RoW Molecular Diagnostics Market, by Technology, 2011 – 2019 (USD Million)
TABLE 17 Competitive Position of Key Players by Segment : Global Molecular Diagnostics Market (2012)

Enquiry Before Buying


Free Market Analysis


Molecular diagnostics primarily refers to a class of diagnostic test that analyzes nucleic acids or proteins at a molecular level. This class of diagnostics is identified as rapidly evolving and fastest growing segment of in-vitro diagnostics industry. Moreover, it is also considered as the most attractive and well established market for clinical applications. Traditionally, usage of molecular diagnostics was limited due to requirement of highly skilled professionals and high cost of tests. But reduction in cost per sample analysis and labor cost, improvements in automation and introduction of advanced technologies has expanded the usage of molecular diagnostics in wide range of applications. The market for molecular diagnostics has expanded since 1990’s with the introduction of PCR test for HIV and Chlamydia Trachomatis/Neisseria Gonorrhoeae (CT/NG). It is estimated that in the U.S. over 600 laboratories and 200 independent laboratories perform molecular diagnostics test to simplify and accelerate the testing process. 

Nowadays, molecular diagnostics tests are widely being adopted for testing infectious diseases (HIV, HCV, HPV HAI and others), genetic diseases, cancer testing and HLA testing. Similarly, molecular diagnostic kits are being used for blood donor screening and pharmacogenetics testing. Growth of this market in various segments is fuelled by the rise in incidence of chronic infections, growing geriatric population, increasing investments in R&D and increasing demand for personalized medicines. Currently, molecular diagnostics revenue is dominated by infectious diseases, capturing more 50% of the market share. Furthermore, growth of this segment will be triggered by rising incidences of hospital acquired infections (HAI) and thus HAI testing market is expected to witness a fastest growth rate in near future. This market is poised to grow at a CAGR of 15.1% from 2013-2019. HAI is being identified as a major cause of death and morbidity among hospitalized patients. It is estimated that each year approximately 14,000 Americans are diagnosed with C.difficile hospital acquired infection each year. Therefore, hospitals continue to adopt HAI testing as more virulent strains of these infections continue to surge. Similarly, rising cancer incidence is expected to drive the market for oncology testing and HPV testing during the analysis period.

Next generation sequencing is growing rapidly and is estimated to emerge as the fastest growing segment. The technique is gaining importance owing to its rapid turnaround time, sensitivity and reduction in cost of sequencing. PCR market that accounted for a maximum share of the total molecular diagnostics market in 2012 is estimated to decline due to evolution of high throughput sequencing techniques.  

Geographically, North America and Europe are most advanced markets in terms of adoption of molecular diagnostic testing and hence account for the majority of the market share. Growth in these regions is driven due to presence of large pool of research laboratories and increased level of public awareness. Moreover, growth in these regions in near future will be driven by growing demand for point of care testing. However, Asian region is expected foresee a high growth during the forecast period of 2013 to 2019. The growth in this region is expected to be fueled by rise in cancer incidence, expanding population base, rising public awareness, and economic developments. Additionally, increased demand for personalized medicines and increasing investments in genomics and proteomics are some other key factors that are likely to propel the market growth in this region. Suppliers therefore can venture into these emerging nations to harness the potential growth opportunities in molecular diagnostics tests. 

Key players of this market include Abbott Laboratories, Roche Diagnostics, Novartis Diagnostics, Hologic Gen-Probe, Qiagen, and Cepheid among others.

global-molecular-diagnostics-market-by-application-2012
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research